Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

2001 • 877 citations

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

2001 • 821 citations

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate

1999 • 458 citations

Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

2001 • 278 citations

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

2002 • 240 citations

Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.

1993 • 238 citations

Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87

1995 • 176 citations

Mylotarg: antibody-targeted chemotherapy comes of age

2001 • 129 citations

IDA‐FLAG (idarubicin, fludarabine, cytarabine, G‐CSF), an effective remission‐induction therapy for poor‐prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial

1998 • 92 citations

MANAGEMENT OF RELAPSED ACUTE MYELOID LEUKAEMIA

1999 • 46 citations

Preliminary report of an ascending dose study of gemtuzumab ozogamicin (mylotarg™, cma-676) in pediatric patients with acute myeloid leukemia

2000 • 11 citations